SynAct Pharma AB (SE:SYNACT)
:SYNACT
Want to see SE:SYNACT full AI Analyst Report?
Top Page
SynAct Pharma AB
(SYNACT)
Select Model
Select Model
Rating:45Neutral
Price Target:
kr16.50
▼(-30.67% Downside)
Action:ReiteratedDate:04/21/26
The score is primarily held back by weak financial performance driven by ongoing losses and heavy, recurring cash burn despite minimal leverage. Technicals add further pressure with price below key moving averages and negative MACD, while valuation is constrained by a negative P/E and no dividend yield data.
Positive Factors
Low Financial Leverage
Very low debt-to-equity reduces near-term solvency risk and preserves strategic optionality. For a clinical-stage biotech this durable balance-sheet conservatism allows management to focus on R&D or negotiate partnerships without immediate refinancing pressure, supporting multi-month program continuity.
Negative Factors
Heavy and Persistent Cash Burn
Sustained negative free cash flow near -97M in 2025 constrains runway and forces recurring financing or deal activity. Over a multi-month horizon this persistent burn elevates dilution risk, limits capacity to expand programs concurrently, and increases dependency on external capital or partnerships.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Financial Leverage
Very low debt-to-equity reduces near-term solvency risk and preserves strategic optionality. For a clinical-stage biotech this durable balance-sheet conservatism allows management to focus on R&D or negotiate partnerships without immediate refinancing pressure, supporting multi-month program continuity.
Read all positive factors
SynAct Pharma AB (SYNACT) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr936.48M
Dividend YieldN/A
Average Volume (3M)214.83K
Price to Earnings (P/E)―
Beta (1Y)0.22
Revenue GrowthN/A
EPS Growth-3.80%
CountrySE
Employees6
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.43
Shares Outstanding53,330,242
10 Day Avg. Volume154,831
30 Day Avg. Volume214,829
Financial Highlights & Ratios
PEG Ratio-2.41
Price to Book (P/B)6.78
Price to Sales (P/S)0.00
P/FCF Ratio-11.86
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.91
Revenue Forecast (FY)N/A
SynAct Pharma AB Business Overview & Revenue Model
Company Description
SynAct Pharma AB, through its subsidiary, SynAct Pharma ApS, develops medicines for acute deterioration in inflammatory diseases. The company is developing AP1189, a drug candidate for the treatment of rheumatoid arthritis and idiopathic membranou...
How the Company Makes Money
SynAct Pharma is a clinical-stage biotech company and does not have widely disclosed, recurring commercial product revenue. Its ability to generate income is therefore primarily tied to financing and potential deal-based monetization. Potential re...
SynAct Pharma AB Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
64
Positive
Cash Flow
25
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | -617.00K | -778.00K | -1.06M | -88.00K |
| EBITDA | -103.55M | -117.15M | -15.40M | -222.70M | -105.71M | -76.62M |
| Net Income | -91.07M | -110.83M | -82.40M | -215.81M | -99.20M | -69.30M |
Balance Sheet | ||||||
| Total Assets | 243.59M | 220.52M | 270.52M | 228.02M | 142.60M | 38.37M |
| Cash, Cash Equivalents and Short-Term Investments | 68.89M | 53.41M | 61.21M | 62.40M | 108.25M | 24.00M |
| Total Debt | 1.54M | 1.81M | 1.88M | 637.00K | 2.06M | 3.09M |
| Total Liabilities | 47.18M | 50.23M | 56.35M | 51.83M | 16.08M | 17.50M |
| Stockholders Equity | 196.41M | 170.29M | 214.17M | 176.19M | 126.52M | 20.87M |
Cash Flow | ||||||
| Free Cash Flow | -41.90M | -97.33M | -89.20M | -100.18M | -117.56M | -65.00M |
| Operating Cash Flow | -41.90M | -97.33M | -89.20M | -100.18M | -117.56M | -65.00M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 370.00K | 27.00K | -6.00K |
| Financing Cash Flow | 40.13M | 90.46M | 87.41M | 53.98M | 200.71M | 74.32M |
SynAct Pharma AB Technical Analysis
Negative
23.80
Price Trends
18.35
Negative
20.03
Negative
20.40
Negative
Market Momentum
-0.27
Negative
40.15
Neutral
23.76
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:SYNACT, the sentiment is Negative. The current price of 23.8 is above the 20-day moving average (MA) of 17.60, above the 50-day MA of 18.35, and above the 200-day MA of 20.40, indicating a bearish trend. The MACD of -0.27 indicates Negative momentum. The RSI at 40.15 is Neutral, neither overbought nor oversold. The STOCH value of 23.76 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:SYNACT.
SynAct Pharma AB Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | kr1.94B | 9.60 | 167.77% | ― | 29.80% | 25.42% | |
55 Neutral | kr935.28M | 7.07 | 81.19% | ― | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | kr508.47M | -4.37 | ― | ― | 125.10% | 29.17% | |
45 Neutral | kr936.48M | -10.42 | -58.41% | ― | ― | -3.80% | |
44 Neutral | kr372.99M | -4.79 | -79.60% | ― | ― | 48.34% | |
42 Neutral | kr20.73M | -0.24 | -186.13% | ― | ― | 19.98% |
* Healthcare Sector Average
SE:SYNACT
SynAct Pharma AB
17.56
-2.54
-12.64%
SE:ONCO
Oncopeptides AB
1.31
-0.41
-24.00%
SE:SANION
Saniona AB
14.06
6.70
91.03%
SE:ACE
Ascelia Pharma AB
2.94
-0.32
-9.82%
SE:GUARD
Guard Therapeutics International AB
1.03
-12.47
-92.39%
SE:CANTA
Cantargia AB
3.76
2.13
130.80%
SynAct Pharma AB Corporate Events
SynAct Pharma Publishes 2025 Annual Report on Inflammatory Disease Pipeline
Apr 15, 2026
SynAct Pharma AB has published its annual report for the financial year 2025, covering the consolidated and parent company financial statements, governance structure and key operational information. The report outlines the company’s clinical...
SynAct Pharma Raises Share Capital Through Directed Issue
Mar 31, 2026
SynAct Pharma has increased its share capital and voting rights following a directed issue of 2,883,725 new shares resolved by the board earlier in March 2026. As a result, the total number of registered shares and votes in the company now stands ...
SynAct Pharma Starts Phase 2 Dengue Trial of Resomelagon in Brazil
Mar 26, 2026
SynAct Pharma has begun dosing patients in its Phase 2 RESOVIR-2 trial, a randomized, placebo-controlled study evaluating oral resomelagon as an add-on therapy in 120 patients with symptomatic Dengue infection in Brazil. The study will assess time...
SynAct Pharma Targets RA Partnerships With BIO-Europe Spring 2026 Showcase
Mar 18, 2026
SynAct Pharma will present and hold partnering meetings at the BIO-Europe Spring 2026 conference in Lisbon, using the high-profile investor and business development forum to showcase its lead candidate resomelagon for rheumatoid arthritis. The com...
SynAct Pharma Sets Capital Markets Day as It Enters Key Clinical Inflection Point
Mar 4, 2026
SynAct Pharma is convening investors, analysts and media for a Capital Markets Day in Stockholm on March 11, positioning its resolution therapy platform at the center of upcoming clinical and strategic milestones. The event underscores the company...
SynAct Pharma Raises SEK 51.9 Million in Directed Share Issue to Strengthen Runway and Deal Leverage
Mar 2, 2026
SynAct Pharma has raised approximately SEK 51.9 million through a directed share issue of 2,883,725 new shares, priced at SEK 18.00 each and placed with Swedish and international qualified investors as well as select existing shareholders. Togethe...
SynAct Pharma Plans SEK 45 Million Directed Share Issue to Bolster Clinical Runway
Mar 2, 2026
SynAct Pharma plans to raise about SEK 45 million via a directed share issue to Swedish and international qualified investors, with pricing set through an accelerated bookbuilding led by Navia Corporate Finance. Major shareholders such as Hunter C...
SynAct Pharma Names New CFO Ahead of Pivotal Phase 2b Data
Feb 24, 2026
SynAct Pharma has appointed Ann Kristin Led as Chief Financial Officer effective 1 March 2026, strengthening its senior leadership as it advances its clinical pipeline. Led brings extensive financial and strategic experience from prior roles at Me...
SynAct Pharma Publishes 2025 Annual Results and Highlights R&D Focus
Feb 18, 2026
SynAct Pharma has released its annual results for January to December 2025, providing an overview of its financial development, research and development progress, and corporate activities. The report highlights significant events in the fourth qua...
SynAct Pharma Advances SEK 5 Million Share Buyback, Reacquires 212,307 Shares
Feb 17, 2026
SynAct Pharma AB has repurchased 212,307 of its own shares under a share buyback program of up to SEK 5 million authorized by its board and shareholders, with transactions executed on Nasdaq Stockholm between 12 January and 12 February 2026. The b...
SynAct Pharma Plans Capital Markets Day Ahead of Key Clinical Readouts
Feb 9, 2026
SynAct Pharma will host a Capital Markets Day in Stockholm on March 11, 2026, to brief investors, analysts, and media on its clinical development programs and strategic priorities. The event comes ahead of key clinical data from the ADVANCE study ...
SynAct Pharma Hits Recruitment Milestone in Phase 2b Rheumatoid Arthritis Trial
Feb 6, 2026
SynAct Pharma has completed recruitment of 240 patients in its 12-week Phase 2b ADVANCE trial evaluating resomelagon in newly diagnosed rheumatoid arthritis patients starting methotrexate therapy, marking a key milestone for its lead asset in infl...
SynAct Pharma Launches Phase 2 RESPIRE Trial of Resomelagon in Viral Respiratory Insufficiency
Jan 30, 2026
SynAct Pharma has initiated a Phase 2 randomized, double-blind, placebo-controlled multicenter study, RESPIRE (SynAct-CS009-RESPIRE), to evaluate resomelagon in 96 patients hospitalized with respiratory insufficiency due to viral infections such a...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.